Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALG-020755
- Development stage
- Preclinical
- Lead developer
- Aligos Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
ALG-020755 is an investigational **small interfering RNA** therapeutic being developed by Aligos Therapeutics for **chronic hepatitis B**. Public company and pipeline materials describe it as a preclinical HBV-directed siRNA program intended to reduce **hepatitis B surface antigen** through **RNA interference**, with the broader therapeutic goal of helping enable functional cure strategies in chronic HBV infection. Available public information on this exact code is limited, but it appears to belong to Aligos' liver-targeted oligonucleotide portfolio and has been characterized publicly as an siRNA candidate that was in **preclinical development** for hepatitis B.
02
Targets
Hepatitis B virus RNA encoding small hepatitis B surface antigen (HBV S-mRNA)
Beyond the preview
Go deeper on ALG-020755.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALG-020755.